Volume 54, Issue 6, Pages (January 1998)

Slides:



Advertisements
Similar presentations
Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup
Advertisements

The proto-oncogene c-Fos transcriptionally regulates VEGF production during peritoneal inflammation Rusan Catar, Janusz Witowski, Philine Wagner, Isa Annett.
Biocompatibility and buffers: Effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function Achim Jörres, Thorsten O. Bender, André.
Role of mesothelial cell-derived granulocyte colony-stimulating factor in interleukin-17- induced neutrophil accumulation in the peritoneum J. Witowski,
Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model  Siska Mortier, Dirk Faict, Norbert.
Volume 55, Issue 2, Pages (February 1999)
Buffer transport in peritoneal dialysis
Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis  James F. Medcalf, Kevin P.G.
Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 
Volume 71, Issue 6, Pages (March 2007)
Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.
Rapamycin in transplantation: A review of the evidence
Innate immunity as a driving force in renal disease
Fibrin plug Kidney International Volume 78, Issue 9, (November 2010)
Volume 64, Issue 6, Pages (December 2003)
Volume 56, Issue 4, Pages (October 1999)
Volume 58, Issue 4, Pages (October 2000)
Fluid overload and residual renal function in peritoneal dialysis: the proof of the pudding is in the eating  Wim Van Biesen, Achim Jörres  Kidney International 
Volume 63, Issue 1, Pages (January 2003)
Volume 60, Issue 5, Pages (November 2001)
Volume 63, Issue 2, Pages (February 2003)
E. Boulanger, N. Grossin, M.-P. Wautier, R. Taamma, J.-L. Wautier 
Methotrexate in the urine
Comorbidity and confounding in end-stage renal disease
Glucose degradation products in peritoneal dialysis fluids: Do they harm?  Janusz Witowski, Achim Jörres, Katarzyna Korybalska, Krzysztof Ksiazek, Justyna.
The epidemiology of chronic kidney disease
Volume 87, Issue 2, Pages (February 2015)
Volume 73, Pages S5-S17 (April 2008)
Claudine S. Bonder, Lisa M. Ebert  Kidney International 
Volume 61, Issue 1, Pages S106-S109 (January 2002)
The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions  P.M. ter Wee, R.H.J. Beelen, J.
Volume 64, Issue 5, Pages (November 2003)
Volume 84, Issue 6, Pages (December 2013)
In vitro biocompatibility performance of Physioneal
Volume 66, Issue 1, Pages (July 2004)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Microbiology and outcomes of peritonitis in North America
Volume 87, Issue 3, Pages (March 2015)
Nephrology Crossword: Peritoneal Dialysis
Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model  Siska Mortier, Dirk Faict, Norbert.
Volume 62, Issue 2, Pages (August 2002)
Volume 66, Issue 3, Pages (September 2004)
Randomized long-term evaluation of bicarbonate-buffered CAPD solution
Volume 60, Issue 6, Pages (December 2001)
Marta Soler, Mercedes Camacho, Ricard Solá, Luís Vila 
Volume 64, Pages S84-S93 (December 2003)
A man with a hole in his penis
Volume 64, Issue 6, Pages (December 2003)
Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomes  Sr. Anne B. Bakewell, Rob M. Higgins, Mair.
Effects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction  Adam G. McLean, Andrew Davenport, Dominic.
Peter G. Blake, Arsh K. Jain, Sechelle Yohanna  Kidney International 
Organ transplantation goes to the movies
Volume 70, Pages S84-S90 (November 2006)
David Z. Levine, M.D., Michelle Iacovitti, Kevin D. Burns, Amy Slater 
Volume 63, Issue 1, Pages (January 2003)
Volume 56, Pages S37-S40 (November 1999)
Volume 54, Issue 6, Pages (January 1998)
Volume 70, Issue 3, Pages (August 2006)
Bradley A. Warady, Mwaffek Bashir, Lynn A. Donaldson 
Volume 62, Issue 4, Pages (October 2002)
Effects of hyperglycemia on the differential expression of insulin and insulin-like growth factor-I receptors in human normal peritoneal and adhesion.
Review of clinical trial experience with icodextrin
Victoria R. Briggs, Badri M. Shrestha, Martin E. Wilkie 
Erratum Kidney International Volume 61, Issue 4, (April 2002)
Volume 65, Issue 1, Pages (January 2004)
T cells and T-cell receptors in acute renal failure
The International Pediatric Peritonitis Registry: Starting to walk
Jason G. Umans, Debra Salvi, Patrick T. Murray, Mark E. Wylam 
Volume 55, Issue 4, Pages (April 1999)
Presentation transcript:

Volume 54, Issue 6, Pages 2184-2193 (January 1998) Biocompatibility and buffers: Effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function  Achim Jörres, Thorsten O. Bender, André Finn, Janusz Witowski, Sibylle Fröhlich, Gerhard M. Gahl, Ulrich Frei, Heiko Keck, Jutta Passlick-Deetjen  Kidney International  Volume 54, Issue 6, Pages 2184-2193 (January 1998) DOI: 10.1046/j.1523-1755.1998.00178.x Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 1 Interleukin-6 release from peritoneal fibroblasts preexposed for up to 90minutes to lactate-buffered, acidic PDF (A) or bicarbonate-buffered, neutral PDF (B) followed by a 24-hour recovery/stimulation period in the presence of IL-1β (100pg/ml). Symbols are: (in A) (□) control; () lactate 1.5%; () lactate 4.25%; (in B) (□) control; () bicarbonate 1.5%; (▪) bicarbonate 4.25%. Data are mean ± sem, N = 6 for lactate-buffered PDF and N = 8 for bicarbonate-buffered PDF. Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 1 Interleukin-6 release from peritoneal fibroblasts preexposed for up to 90minutes to lactate-buffered, acidic PDF (A) or bicarbonate-buffered, neutral PDF (B) followed by a 24-hour recovery/stimulation period in the presence of IL-1β (100pg/ml). Symbols are: (in A) (□) control; () lactate 1.5%; () lactate 4.25%; (in B) (□) control; () bicarbonate 1.5%; (▪) bicarbonate 4.25%. Data are mean ± sem, N = 6 for lactate-buffered PDF and N = 8 for bicarbonate-buffered PDF. Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 1 Interleukin-6 release from peritoneal fibroblasts preexposed for up to 90minutes to lactate-buffered, acidic PDF (A) or bicarbonate-buffered, neutral PDF (B) followed by a 24-hour recovery/stimulation period in the presence of IL-1β (100pg/ml). Symbols are: (in A) (□) control; () lactate 1.5%; () lactate 4.25%; (in B) (□) control; () bicarbonate 1.5%; (▪) bicarbonate 4.25%. Data are mean ± sem, N = 6 for lactate-buffered PDF and N = 8 for bicarbonate-buffered PDF. Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 1 Interleukin-6 release from peritoneal fibroblasts preexposed for up to 90minutes to lactate-buffered, acidic PDF (A) or bicarbonate-buffered, neutral PDF (B) followed by a 24-hour recovery/stimulation period in the presence of IL-1β (100pg/ml). Symbols are: (in A) (□) control; () lactate 1.5%; () lactate 4.25%; (in B) (□) control; () bicarbonate 1.5%; (▪) bicarbonate 4.25%. Data are mean ± sem, N = 6 for lactate-buffered PDF and N = 8 for bicarbonate-buffered PDF. Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 2 Interleukin-6 release from peritoneal mesothelial cells pre-exposed for up to 60minutes to lactate-buffered acidic PDF (A) or bicarbonate-buffered neutral PDF (B) followed by a 24-hour recovery/stimulation period in the presence of IL-1β (100pg/ml). Symbols are: (in A) (□) control; () lactate 1.5%; () lactate 4.25%; (in B) (□) control; () bicarbonate 1.5%; (▪) bicarbonate 4.25%. Data are mean ± sem, N = 6 for both lactate-buffered and bicarbonate-buffered PDF. *Statistical significance (P < 0.05) versus controls (cell culture medium) at the corresponding time point. Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 2 Interleukin-6 release from peritoneal mesothelial cells pre-exposed for up to 60minutes to lactate-buffered acidic PDF (A) or bicarbonate-buffered neutral PDF (B) followed by a 24-hour recovery/stimulation period in the presence of IL-1β (100pg/ml). Symbols are: (in A) (□) control; () lactate 1.5%; () lactate 4.25%; (in B) (□) control; () bicarbonate 1.5%; (▪) bicarbonate 4.25%. Data are mean ± sem, N = 6 for both lactate-buffered and bicarbonate-buffered PDF. *Statistical significance (P < 0.05) versus controls (cell culture medium) at the corresponding time point. Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 2 Interleukin-6 release from peritoneal mesothelial cells pre-exposed for up to 60minutes to lactate-buffered acidic PDF (A) or bicarbonate-buffered neutral PDF (B) followed by a 24-hour recovery/stimulation period in the presence of IL-1β (100pg/ml). Symbols are: (in A) (□) control; () lactate 1.5%; () lactate 4.25%; (in B) (□) control; () bicarbonate 1.5%; (▪) bicarbonate 4.25%. Data are mean ± sem, N = 6 for both lactate-buffered and bicarbonate-buffered PDF. *Statistical significance (P < 0.05) versus controls (cell culture medium) at the corresponding time point. Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 2 Interleukin-6 release from peritoneal mesothelial cells pre-exposed for up to 60minutes to lactate-buffered acidic PDF (A) or bicarbonate-buffered neutral PDF (B) followed by a 24-hour recovery/stimulation period in the presence of IL-1β (100pg/ml). Symbols are: (in A) (□) control; () lactate 1.5%; () lactate 4.25%; (in B) (□) control; () bicarbonate 1.5%; (▪) bicarbonate 4.25%. Data are mean ± sem, N = 6 for both lactate-buffered and bicarbonate-buffered PDF. *Statistical significance (P < 0.05) versus controls (cell culture medium) at the corresponding time point. Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Figure 3 Interleukin-6 release from IL-1β-stimulated peritoneal fibroblasts coincubated with serial dilutions (vol/vol) of lactate-buffered (A, 1.5% glucose, N = 6; B, 4.25% glucose) or bicarbonate-buffered peritoneal dialysis fluids (C, 1.5% glucose, N = 9; D, 4.25% glucose, N = 7). *Statistical significance (P < 0.05) versus controls (cell culture medium). Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 2184-2193DOI: (10. 1046/j. 1523-1755 Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 2184-2193DOI: (10. 1046/j. 1523-1755 Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 2184-2193DOI: (10. 1046/j. 1523-1755 Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions

Kidney International 1998 54, 2184-2193DOI: (10. 1046/j. 1523-1755 Kidney International 1998 54, 2184-2193DOI: (10.1046/j.1523-1755.1998.00178.x) Copyright © 1998 International Society of Nephrology Terms and Conditions